Efecto del compuesto correlacionado de hexosa activo (AHCC) en patologías inflamatorias intestinalestriquinosis y enfermedad inflamatoria intestinal (EII)

  1. López Cauce, Beatriz
Zuzendaria:
  1. Juan José García Rodríguez Zuzendaria
  2. Marta Puerto Cantero Zuzendaria
  3. Luis Alberto Menchén Viso Zuzendaria

Defentsa unibertsitatea: Universidad Complutense de Madrid

Fecha de defensa: 2021(e)ko ekaina-(a)k 04

Epaimahaia:
  1. Eduardo Martínez Naves Presidentea
  2. Alicia Gómez Barrio Idazkaria
  3. José Antonio Pajares Díaz Kidea
  4. Rosa Maria Del Campo Moreno Kidea
  5. Manuel Barreiro de Acosta Kidea
Saila:
  1. Medicina

Mota: Tesia

Teseo: 155649 DIALNET lock_openDocta Complutense editor

Laburpena

AHCC is a natural product discovered in 1986 and patented by the Japanese company Amino up, which is obtained from the fermentation of the mycelium of the L. edodes fungus. It is described as a nutraceutical or an immunomodulator due to its ability to modulate the immune response to challenges of different etiology (1). Currently, it is used as concomitant treatment in cancer patients, since it reduces the generalized effects of chemotherapy (2-5).In the present work, we wanted to test the effects of AHCC in an organ where the regulation of the immune system is fundamental: the intestine. To do this, several models were used: the murine model of trichinosis and models of inflammatory bowel disease (IBD), both acute and chronic (6, 7)...